Aurofusarin


CAS No. : 13191-64-5

13191-64-5
Price and Availability of CAS No. : 13191-64-5
Size Price Stock
100 mg Get quote
250 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-120805
M.Wt: 570.46
Formula: C30H18O12
Purity: >98 %
Solubility:
Introduction of 13191-64-5 :

Aurofusarin is a secondary metabolite. Aurofusarin catalytically inhibits topoisomerase II alpha, induces CYP1A1, p53, oxidative stress, DNA damage, and glutathione redox shift, intercalates into DNA, and causes S phase reduction accompanied by cytoskeletal/nuclear condensation. Aurofusarin disrupts intestinal epithelial barrier integrity, acts additively with deoxynivalenol, reduces mitochondrial activity, is cytotoxic to colon cells, and inhibits probiotic Gram-positive bacteria through outer membrane penetration without affecting Gram-negative bacteria. Aurofusarin can be used in research on colon cancer and bacterial infections[1][2][3][4][5][6][7][8]. In Vitro:Aurofusarin shows relatively low toxicity against Spodoptera frugiperda Sf9 insect cells in the MTT assay[1].
Aurofusarin (5-10 µM; 24-72 h) decreases the TEER of differentiated IPEC-J2 at 10 µM, with a maximum reduction of 83% after 72 h, whereas 5 µM had no effect and viability was unaffected[2].
Aurofusarin (5 µM; 24-48 h) combined with DON (6-Diazo-5-oxo-L-nor-Leucine) (HY-108357) additively reduces the TEER of differentiated IPEC-J2 at 24 and 48 h without affecting viability[2].
Aurofusarin (1-10 μM; 1 h) inhibits human topoisomerase II α catalytic activity at concentrations ≥1 μM in a cell-free decatenation assay[3].
Aurofusarin (10 μM; 24 h) increases CYP1A1 activity in HT29 cells[3].
Aurofusarin (0.01-10 μM; 24 h) reduces mitochondrial activity in HT29 and HCEC-1CT cells[3].
Aurofusarin (0.01-10 μM; 24-72 h) inhibits the proliferation of HT29 and HCEC-1CT cells, with HCEC-1CT responding at 0.1 μM after 72 h, and both cell lines being strongly inhibited at 10 μM[3].
Aurofusarin (5-10 μM; 1-24 h) induces p53 but not γ-H2AX in HT29 and HCEC-1CT cells, and disrupts actin cytoskeleton morphology, especially in HCEC-1CT cells[3].
Aurofusarin (5-10 μM; 24 h) reduces S-phase cells in HT29 cells without altering the cell cycle distribution of HCEC-1CT cells[3].
Aurofusarin (0.01-10 μM; 1 h) induces DNA strand breaks in HT29 cells at 1 μM and induces fpg-sensitive oxidative DNA damage at concentrations ≥0.1 μM[3].
Aurofusarin (0.01-10 μM; 1-3 h) induces reactive oxygen species in HT29 cells[3].
Aurofusarin (0.01-10 μM; 1-24 h) alters the glutathione redox state in HT29 cells, decreasing tGSH and increasing the GSSG/GSH ratio[3].
Aurofusarin (0.01-10 μM; 3-24 h) induces CYP1A1 transcription in HT29 cells, reaching 8.1-fold after 3 h at 5 μM and 6.5-fold after 24 h at 10 μM, while decreasing γGCL after 3 h at 10 μM[3].
Aurofusarin (2-256 µM; 6 h) inhibits the growth of Lactobacillus acidophilus in vitro with an IC50 of 8 µM, and had no effect on Escherichia coli, Staphylococcus aureus, or Salmonella typhimurium[5].

Your information is safe with us.